Greenspace Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Collaborative care platform for mental health measurement and outcomes tracking, Toronto Canada. Helps health systems use data to improve patient mental health outcomes.
About
Greenspace Health is a Toronto, Canada-based digital health company founded in 2015 that provides a collaborative care platform designed to embed measurement-based care practices into mental health and primary care settings. The platform enables clinicians and care teams to systematically collect, track, and act on patient-reported outcome measures (PROMs), bringing data-driven decision-making to mental health treatment in a way that mirrors how chronic disease management is handled in other medical specialties.\n\nThe Greenspace platform supports the collection of validated clinical measurement tools such as the PHQ-9 (depression), GAD-7 (anxiety), and dozens of other standardized instruments, delivered to patients via mobile or web between sessions. Clinicians receive visualized outcome trends, alerts for deteriorating patients, and population-level dashboards that allow managers to identify care gaps and resource needs. The system is designed to integrate with existing EHRs and fit into existing clinical workflows rather than replace them.\n\nGreenspace primarily serves health systems, community mental health centers, and primary care organizations in Canada and the United States that are implementing collaborative care models or value-based mental health contracts. As payers and government health agencies increase pressure on providers to demonstrate mental health treatment outcomes, Greenspace is positioned as essential infrastructure for outcomes accountability. The company has partnered with several provincial health systems in Canada and is expanding its US footprint through health system partnerships.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.